Skip to main content

Table 3 Multivariate analysis

From: Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death

PSA Progression-Free Survival

  

Model 1

  

Model 2

  

Model 3

 
 

HR

(95%CI)

p=

HR

(95%CI)

p=

HR

(95%CI)

p=

PSA,ng/ml

         

≤10ng/ml

1.0

  

1.0

  

1.0

  

>10ng/ml

1.41

(0.67-2.97)

0.4

1.26

(0.59-2.68)

0.5

1.30

(0.61-2.79)

0.5

Extra-prostatic extension

Yes

1.0

  

1.0

  

1.0

  

No

3.33

(1.31-8.49)

0.01

3.21

(1.28-8.07)

0.01

3.21

(1.27-8.09)

0.01

Pelvic nodes involved

N0

1.0

  

1.0

  

1.0

  

N+

1.56

(0.69-3.56)

0.3

1.38

(0.60-3.14)

0.4

1.40

(0.61-3.18)

0.4

Surgical margins involved

No

1.0

  

1.0

  

1.0

  

Yes

0.75

(0.31-1.79)

0.5

0.72

(0.31-1.67)

0.4

0.68

(0.29-1.62)

0.4

Seminal vesicles involved

No

1.0

  

1.0

  

1.0

  

Yes

0.77

(0.35-1.68)

0.5

0.64

(0.28-1.43)

0.3

0.64

(0.28-1.42)

0.3

Gleason score

<7

1.0

        

≥7

2.03

(0.91-4.55)

0.08

      

Gleason score

≤7

   

1.0

     

>7

   

3.29

(1.63-6.65)

0.001

   

Gleason score

<7

      

1.0

 

0.003

=7

      

1.33

(0.54-3.26)

0.5

>7

      

3.90

(1.59-9.55)

0.003

Epithelial IRS

>2

1.0

  

1.0

  

1.0

  

≤2

6.20

(1.30-29.44)

0.02

4.85

(0.98-24.09)

0.05

4.86

(0.98-24.05)

0.05

Stroma IRS

<12

1.0

  

1.0

  

1.0

  

=12

2.06

(0.87-4.88)

0.1

1.90

(0.77-4.65)

0.1

1.84

(0.76-4.50)

0.6

  1. Abbreviations:HR, Hazard Ratio;CI,Confidence Interval;PSA,Prostate-specific antigen;IRS,Immuno-reactive score.